GlassScriptPhysician profile
Marjorie Matheny
NPI 1679110316
$3,384.48
in general payments reported to CMS, 2019-2025
29 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $494 · 2022: $984 · 2023: $916 · 2024: $796 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,907.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $408.55 | 2023-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.68 | 2021-2024 | Jardiance |
| Pfizer INC. | $377.84 | 2021-2024 | |
| Amgen INC. | $259.95 | 2021-2023 | Repatha |
| Cvrx, INC. | $251.69 | 2021-2025 | Barostim Neo System |
| Medtronic, INC. | $201.78 | 2021-2023 | Micra, Reveal Linq, Linq II |
| Novartis Pharmaceuticals Corporation | $191.61 | 2021-2024 | |
| Abiomed | $148.23 | 2024-2025 | Impella |
| Actelion Pharmaceuticals US, INC. | $138.49 | 2021-2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $114.35 | 2022-2023 | Camzyos |
| Merck Sharp & Dohme LLC | $113.30 | 2022-2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $109.77 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $97.81 | 2021-2024 | |
| Biosense Webster, INC. | $93.49 | 2022 | |
| Alnylam Pharmaceuticals INC. | $63.65 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $63.03 | 2023-2024 | Nexletol |
| Novo Nordisk INC | $55.61 | 2021-2022 | |
| Amarin Pharma, INC. | $55.02 | 2021 | |
| Impulse Dynamics (USA) INC. | $38.20 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $31.46 | 2023-2024 | Inpefa |
| Imperative Care, INC | $30.93 | 2024 | Symphony Catheter |
| Edwards Lifesciences Corporation | $25.19 | 2021 | |
| Boston Scientific Corporation | $23.91 | 2024 | Lux-Dx Insertable Cardiac Monitor |
| Shockwave Medical, INC | $23.84 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.14 | 2024 | Evkeeza |
| Philips North America LLC | $19.99 | 2023 | |
| Gilead Sciences, INC. | $18.53 | 2021 | |
| Scpharmaceuticals INC. | $14.66 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $12.78 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marjorie Matheny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.